Detection of Circulating Tumor Cells in Castration-Resistant Prostate Cancer
Metastasis from primary tumors is responsible for most cancer deaths. Several reports have suggested that early-stage cancer has the potential to begin shedding cancer cells into the circulation early in development. Several groups have noted that levels of circulating tumor cells (CTCs) in patients parallel the tumor burden and response to therapy. There are multiple approaches to detecting CTCs. CTCs at baseline are a strong, independent prognostic biomarker. In addition, measuring CTCs at any time point predicts the response to therapy. The goal of the present chapter is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker in prostate cancer patients.
KeywordsCirculating tumor cells Castration-resistant prostate cancer Biomarker
- 24.Steinestel J, Luedeke M, Arndt A, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015. https://doi.org/10.18632/oncotarget.3925.
- 27.Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56.CrossRefGoogle Scholar
- 30.Antonarakis ES, Lu C, Luber B, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA. 2015;1(5):582–91.Google Scholar